

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/762,794	· 03/23/2001	Robert S. Lowe	20276P	1127
210 7	590 11/05/2002			
MERCK AND CO INC			EXAMINER	
P O BOX 2000 RAHWAY, NJ 070650907			SULLIVAN, DANIEL M	
			ART UNIT	PAPER NUMBER
			1636	1/
	DATE MAILED: 11/05/2002		16	

Please find below and/or attached an Office communication concerning this application or proceeding.

r		Application No.	Applicant(s)			
	•	09/762,794	LOWE ET AL.			
Office Action Summary		Examin r	Art Unit			
	,					
T	The MAILING DATE of this communication and	Daniel M Sullivan	orrespondence address			
The MAILING DATE of this communication appears on the cover sh t with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 2 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status						
1)	Responsive to communication(s) filed on					
2a)□		— is action is non-final.				
3)⊠ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims						
4)🖂	Claim(s) 1-10 and 12 is/are pending in the app	olication.				
	4a) Of the above claim(s) is/are withdraw	vn from consideration.				
5)	5) Claim(s) is/are allowed.					
6)	6) Claim(s) is/are rejected.					
7)🖂	Claim(s) 1-10 and 12 is/are objected to.					
8) Claim(s) are subject to restriction and/or election requirement.						
Application Papers						
	The specification is objected to by the Examine					
10)[10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.					
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
11)⊠ The proposed drawing correction filed on <u>15 October 2002</u> is: a)⊠ approved b)□ disapproved by the Examiner.						
If approved, corrected drawings are required in reply to this Office action.						
12) The oath or declaration is objected to by the Examiner.						
Priority under 35 U.S.C. §§ 119 and 120						
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a) ☐ All b) ☐ Some * c) ☐ None of:						
1. Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No						
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 						
14)⊠ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).						
a) ☐ The translation of the foreign language provisional application has been received. 15)☑ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.						
Attachment(s)						
2) Notic	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Informal F	(PTO-413) Paper No(s) Patent Application (PTO-152) Pation Sheet .			

Continuation of Attachment(s) 6). Other: Notice to comply with requirements for patent applications containing sequence disclosures and CRF Problem Report.

Art Unit: 1636

DETAILED ACTION

This Office Action is a response to the Amendment under 37 CFR § 1.116 (Paper No. 12), Affidavit of Prior Invention under 1.131 (Paper No. 15), sequence listing (Paper No. 13) and CRF filed October 15, 2002. The amendment and Affidavit have been entered in the case.

Sequence Compliance

Claim Rejections - 35 USC § 102(e)

Rejection of claims 5-7 as being anticipated by Hallek et al. is withdrawn in view of the Declaration under 37 CFR 1.131 (Paper No. 15), wherein William L. McClements declares that "he and the other named co-applicants constructed a nucleic acid encoding a fusion protein comprising a first segment comprising a nucleic acid encoding a portion of an HPV L2 protein which is less than a full-length sequence, and a second segment comprising a nucleic acid encoding a peptide or protein in the United States before February 20, 1998".

Conclusion

This application is in condition for allowance except for the following formal matters:

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). A computer readable form (CRF) of the sequence listing was submitted. However, the CRF could not be processed by the Scientific and Technical Information Center (STIC) for the reason(s) set , Application/Control Number: 09/762,794

Art Unit: 1636

É . , 🛶

forth on the attached CRF Diskette Problem Report. Please note the special address for

submission of genetic sequence on diskette or CD-Rom set forth on the CRF Problem Report.

Prosecution on the merits is closed in accordance with the practice under Ex parte

Quayle, 1935 C.D. 11, 453 O.G. 213.

A shortened statutory period for reply to this action is set to expire **TWO MONTHS**

from the mailing date of this letter.

Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Daniel M Sullivan whose telephone number is 703-305-4448.

The examiner can normally be reached on Monday through Friday 8-4:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Irem Yucel can be reached on 703-305-1998. The fax phone numbers for the

organization where this application or proceeding is assigned are 703-746-9105 for regular

communications and 703-746-9105 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding

should be directed to the receptionist whose telephone number is 703-308-0196.

dms

November 1, 2002

JAMES KETTER PRIMARY EXAMINER Page 3

Application No. M. L. 194

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 -1.825 for the following reason(s): This application clearly fails to comply with the requirements of 37 CFR 1.821 Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c). 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing." The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d). The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e). 7. Other: -Applicant must provide: An initial or substitute computer readable form (CRF) copy of the "Sequence Llisting" An initial or substitute paper copy of the "Sequence Listing", as well as an amen'dment directing its entry into the specification A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d) For questions regarding compliance with these requirements, please contact:

For Rules Interpretation, call (703) 308-1123 For CRF submission help, call (703) 308-4212 For PatentIn software help, call (703) 557-0400